ACE and cardiomyopathy: In patients with chemotherapy-induced cardiomyopathy, those treated with a combination of ACE-inhibitor (ACEi) and BB had significant improvement in LVEF (26% ± 10.20% versus 37% ± 17.6%, p = 0.028), which was not seen with Angiotensin converting enzyme inhibitor (ACEi) treatment alone [52].